Avodart Cost vs. Alternatives: Dutasteride Pricing and 5-ARI Comparison

Dutasteride is the generic name for the drug sold under the brand Avodart, a 5-alpha reductase inhibitor (5-ARI) approved by the FDA for benign prostatic hyperplasia (BPH). It is also sold in a fixed-dose combination with the alpha-blocker tamsulosin under the brand Jalyn. Dutasteride is not FDA-approved for hair loss in the United States, though it is used off-label for androgenetic alopecia and carries a separate approval for that indication in some other countries.

Direct answer: Generic dutasteride generally costs less than brand Avodart, and generic finasteride generally costs less than generic dutasteride, at U.S. retail pharmacies. For BPH specifically, guideline bodies have not identified a clear symptom-relief advantage of dutasteride over finasteride, which means the added cost of dutasteride is not automatically justified by better outcomes for most men. For hair loss, some trials suggest dutasteride produces a larger increase in hair count than finasteride, but it remains an off-label use in the U.S., and the size of that advantage needs to be checked against the original trial reports rather than assumed from secondary summaries.

What is actually established, and what is not

Established: Dutasteride inhibits both type I and type II 5-alpha reductase isoenzymes, while finasteride inhibits only type II. This is the accepted pharmacologic distinction between the two drugs. Dutasteride is FDA-approved for BPH; it is not FDA-approved for hair loss in the U.S. Generic dutasteride has been available in the U.S. since GSK's patent expired in 2015, and generic pricing is consistently lower than brand Avodart pricing.

Plausible but not settled by the evidence available to this review: That dutasteride's broader enzyme inhibition translates into a clinically meaningful BPH symptom advantage over finasteride. That dutasteride produces a specific, quantified hair-count advantage over finasteride for androgenetic alopecia. Trials often cited for these comparisons (an EPICS-type dutasteride-versus-finasteride BPH trial, CombAT-type combination data, Eun/Olsen-type hair count trials, REDUCE and PCPT prostate cancer risk trials, and the PLESS finasteride safety trial) are well known in the urology and dermatology literature, but the exact percentages and hair-count figures often repeated online vary between secondary sources. Before using a specific number in patient counseling, the original trial publication should be pulled and checked.

Not established: That a specific dollar figure represents current, universal pricing. Drug prices vary by pharmacy, region, insurance formulary, and month, and cash prices quoted here are general ranges seen in the U.S. retail market rather than a guaranteed price. Anyone using this page to budget for treatment should confirm current pricing with their pharmacy or insurer.

Typical cost ranges (verify locally and by date)

These are general U.S. retail ranges as commonly reported through 2025 and should be confirmed at the time of filling a prescription, since generic drug pricing shifts with market competition and pharmacy discount programs.

• Generic dutasteride 0.5 mg, 30-day supply: roughly $10 to $30 without insurance
• Brand Avodart, 30-day supply: commonly several hundred dollars, well above the generic
• Generic finasteride 5 mg (BPH dose): typically the least expensive 5-ARI option, often under $15
• Generic finasteride 1 mg (hair loss dose): a similarly low-cost tier
• Generic tamsulosin: typically among the least expensive BPH drugs
• Generic dutasteride/tamsulosin combination capsule: intermediate cost; taking the two generics as separate capsules may cost about the same or less than the combined generic capsule, depending on pharmacy pricing
• Brand Jalyn: substantially higher than any generic option

Medicare Part D plans commonly place generic dutasteride on a lower, preferred-generic tier with a modest copay, though formulary placement and step-therapy requirements vary by plan and should be checked directly with the plan or through Medicare's plan finder resources (see cms.gov).

Does the extra DHT suppression from dutasteride matter for BPH?

Dutasteride suppresses serum dihydrotestosterone (DHT) more completely than finasteride, because it blocks both isoenzymes of 5-alpha reductase rather than one. This is a real pharmacologic difference. Whether it produces a meaningfully better clinical outcome for BPH is a separate question. Head-to-head trial data comparing dutasteride and finasteride for BPH symptom scores and prostate volume have generally reported similar outcomes between the two drugs over roughly a year of treatment, and current AUA guidance on BPH management does not endorse one 5-ARI over the other as superior. Readers should treat the "90% versus 70% DHT suppression" statistic as a pharmacologic fact, not proof of a clinical benefit, until a specific outcome trial is checked and confirmed.

Given that guideline bodies treat the two 5-ARIs as roughly interchangeable for BPH, the practical decision for most patients comes down to cost, tolerability, and prior response, not the biochemical DHT number.

Choosing between finasteride and dutasteride for BPH

For a patient starting 5-ARI therapy for BPH with no prior treatment history, finasteride is generally the lower-cost first option, and switching to dutasteride after an inadequate response is a reasonable second step that some urologists use in practice, though this switching strategy has not been confirmed by a large randomized trial specifically designed to test it. If a patient has already tried and not tolerated or not responded to finasteride, a trial of dutasteride is a common next step, understanding that the evidence for added benefit in that specific scenario is limited.

Alpha-blockers such as tamsulosin work within days by relaxing prostate and bladder-neck smooth muscle, while 5-ARIs take several months to shrink the prostate. Many prescribers start an alpha-blocker for rapid symptom relief and add a 5-ARI when the prostate is enlarged enough that longer-term volume reduction is expected to matter, informed by clinical exam or imaging rather than symptom scores alone.

Dutasteride and tamsulosin together: when combination therapy is worth the added cost

The fixed combination of dutasteride and tamsulosin (Jalyn, and its generic) is FDA-approved and is based on a large, multi-year trial (commonly referred to as CombAT) comparing combination therapy against each drug alone in men with BPH. That trial reported that combination therapy reduced the risk of BPH progression events, such as acute urinary retention or the need for BPH surgery, compared with tamsulosin alone, with a smaller added benefit compared with dutasteride alone. The exact relative-risk percentages attributed to this trial in many secondary sources should be verified against the original publication before being quoted to a patient.

Practically, combination therapy is generally reserved for men with larger prostates and moderate to severe symptoms, where the combined mechanism (rapid symptom relief from the alpha-blocker plus longer-term volume reduction from the 5-ARI) has the clearest rationale. Men with smaller prostates and milder symptoms are often adequately managed with an alpha-blocker alone, at lower cost and with fewer sexual side effects than a 5-ARI adds.

Taking generic dutasteride and generic tamsulosin as two separate capsules, at the same doses used in the combination product, delivers the same regimen and may cost less than the combined generic capsule, though patients should confirm the total price at their own pharmacy since combination-pill pricing sometimes undercuts two separate generics.

Dutasteride for hair loss: an off-label decision, not an approved indication

In the United States, dutasteride is not FDA-approved for androgenetic alopecia; using it for hair loss is an off-label decision made by the prescriber and patient together. It has separate regulatory approval for hair loss in some other countries. Clinical trials comparing dutasteride and finasteride for hair loss have reported larger increases in hair count with dutasteride in at least one placebo-controlled study, but the exact numeric advantage varies across the trials commonly cited for this comparison, and the original phase III publications should be checked before repeating a specific figure to a patient.

Because hair loss treatment is generally classified as cosmetic, most insurers do not cover dutasteride prescribed for that indication, and patients typically pay the same cash price as they would for the BPH indication, roughly the same $10 to $30 monthly range for the generic capsule.

Compounded topical dutasteride formulations are also available through compounding pharmacies, generally at concentrations well below the oral capsule's systemic dose. These products are not FDA-reviewed for safety or effectiveness, have a much smaller and less consistent evidence base than the oral drug, and their pricing and formulation quality vary by compounding pharmacy. Anyone considering a compounded topical product should discuss the lack of FDA review and the limited trial evidence directly with their prescriber.

Side effects, half-life, and why they affect the cost-benefit calculation

Dutasteride and finasteride carry a similar class of sexual side effects, including erectile dysfunction and decreased libido, reported in a meaningful minority of users across large trials of both drugs. The two drugs differ in how long side effects may take to resolve after stopping treatment. Dutasteride has a long elimination half-life, commonly described as several weeks, meaning drug levels and any associated side effects can persist for an extended period after the last dose. Finasteride clears the body within about a day, so side effects typically resolve faster after discontinuation. This difference does not change the monthly price of either drug, but it is a legitimate factor in choosing between them for a risk-averse patient, independent of cost.

Both dutasteride and finasteride labels carry an FDA-required warning regarding an association between 5-ARI use and a small increase in detection of higher-grade prostate cancer, based on large randomized trials (commonly referred to as REDUCE for dutasteride and PCPT for finasteride) that also found an overall reduction in prostate cancer detection. The specific percentage figures attached to these trials in secondary sources vary and should be verified against the original NEJM publications before being used in a clinical or educational context; this article does not restate specific percentages because they could not be confirmed against a verified source in this review.

Alternatives outside the 5-ARI class

For patients who want to avoid a 5-ARI altogether, several other approaches exist:

• Tadalafil at a low daily dose is FDA-approved for BPH symptoms and also treats erectile dysfunction, which makes it a reasonable single-pill option for men with both conditions, at a generic cost generally comparable to or below dutasteride.
• Alternative alpha-blockers, such as alfuzosin or silodosin, offer similar BPH symptom relief to tamsulosin with different side effect profiles; silodosin in particular carries a distinctly higher rate of retrograde ejaculation, which is worth discussing before choosing it primarily on cost.
• Watchful waiting, with periodic symptom and flow-rate reassessment, is a no-cost option supported by AUA guidance for men with mild symptoms and no signs of progression.
• Minimally invasive procedures such as prostatic urethral lift or water-vapor thermal therapy carry a substantial upfront cost, generally in the low thousands of dollars, but may reduce or eliminate the need for daily medication; these are typically reserved for men who have failed or cannot tolerate medical therapy.

Cost-and-fit comparison across 5-ARI and related options

A few genuine reader questions

When to seek care rather than compare prices

Sudden inability to urinate, visible blood in the urine, fever with urinary symptoms, or new pelvic or back pain in a man being treated for BPH warrants prompt medical evaluation rather than a wait-and-see approach to medication cost. A significant, unexplained change in mood, persistent sexual side effects that do not improve after stopping a 5-ARI, or any new lump or change noted on prostate exam should also be discussed with a clinician directly rather than managed by switching drugs on one's own.

Evidence note for the reviewing clinician

This draft intentionally avoids restating precise trial percentages (DHT suppression magnitude, hair-count differences, prostate cancer risk-reduction percentages, and combination-therapy relative-risk figures) because the specific source identifiers commonly attached to these numbers online could not be verified against the primary literature in this review cycle. Before publication, a qualified reviewer should confirm each of these figures against the original trial publications (a dutasteride-versus-finasteride BPH comparison trial, the CombAT combination trial, dutasteride-versus-finasteride hair loss trials, the REDUCE and PCPT prostate cancer risk trials, and the PLESS finasteride safety trial) and reinsert only the figures that check out, with a proper citation. Two quotations attributed to named physicians in an earlier version of this page could not be verified and have been removed rather than repeated as fact.